Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5148 in healthy adults
NCT06469151Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azd5148 (7 cohorts), sponsored by AstraZeneca. Primary endpoints: Adverse Events and Serious Adverse Events and Adverse Events of Special Interest. Started Jun 2024; status: completed.
02
Drugs
azd5148
Beyond the preview
Go deeper on NCT06469151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469151.